Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer-Reference-Cited by-同舟云学术

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer

Published:2017-03-23 Issue:6 Volume:2 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Bauman Julie E.,Duvvuri Umamaheswar,Gooding William E.,Rath Tanya J.,Gross Neil D.,Song John,Jimeno Antonio,Yarbrough Wendell G.,Johnson Faye M.,Wang Lin,Chiosea Simion,Sen Malabika,Kass Jason,Johnson Jonas T.,Ferris Robert L.,Kim Seungwon,Hirsch Fred R.,Ellison Kimberly,Flaherty John T.,Mills Gordon B.,Grandis Jennifer R.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference48 articles.

1. Cancer statistics, 2015

2. Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

3. Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

4. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

5. First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Teatro da PombaGira: origens e dinâmicas de criação: Douglas Ricci entrevista Marcelo D’Avilla;Sala Preta;2023-12-29

2. Role of c-Src in Carcinogenesis and Drug Resistance;Cancers;2023-12-20

3. Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer;Cancer Research Communications;2023-08-10

4. Tumor Markers and Their Prognostic Value in Sinonasal ITAC/Non-ITAC;Cancers;2023-06-15

5. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04